Clinical Implications of an Integrated Clinical and Biological Staging Scheme for Alzheimer’s Disease
The integration of clinical and biological staging has significant potential in clinical practice by providing information about copathologies, underlying neurodegeneration, and the progression of AD.
Authors
- Seun Jeon (ORCID: https://orcid.org/0000-0003-2817-3352)
- Mijin Yun (ORCID: https://orcid.org/0000-0002-1712-163X)
- Sung Woo Kang (ORCID: https://orcid.org/0000-0001-9791-6899)
- Byoung Seok Ye (ORCID: https://orcid.org/0000-0003-0187-8440)
- Young‐gun Lee (ORCID: https://orcid.org/0000-0003-0460-455X)
- Sangwon Lee (ORCID: https://orcid.org/0000-0003-1982-2605)
Institutions
- Yonsei University (KR)
- Inje University Ilsan Paik Hospital (KR)
- Hanyang University (KR)
Publication Details
- Journal
- Journal of Clinical Neurology
- Published
- 2025-01-01
- DOI
- https://doi.org/10.3988/jcn.2025.0218
- Citations
- 2
- Primary Topic
- Dementia and Cognitive Impairment Research
- Type
- article
- Field-Weighted Citation Impact
- 2.94
Funders
- U.S. Department of Defense
- Alzheimer's Association
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- Biogen
- University of Southern California
- F. Hoffmann-La Roche
- Meso Scale Diagnostics
- BioClinica
- Novartis Pharmaceuticals Corporation
- Northern California Institute for Research and Education
- Inje University
- Eisai
- Servier
- H. Lundbeck A/S
- IXICO
- National Institutes of Health
- Genentech
- Canadian Institutes of Health Research